Microdosing Tirzepatide: Is It Safe? Dose Chart and Risks

What Microdosing Tirzepatide Means

Start with the plain fact that there is no agreed definition. TODAY.com quotes doctors explaining that microdosing generally means taking a much lower dose of a GLP-1 medicine, in this case tirzepatide, than the amount the FDA recommends and the manufacturer indicates.¹⁸ Cleveland Clinic describes it as intentionally taking a reduced amount, giving the example of someone with a 15 mg (labelled dose, not a recommendation, Mounjaro FDA label) Mounjaro prescription who takes only a portion of it.¹³ This page is the tirzepatide entry in our wider look at microdosing GLP-1 medicines.

Two working forms show up across the sources. The first is injecting an amount smaller than the lowest labelled dose. Hackensack Meridian Health frames it for tirzepatide directly: the lowest dose studied and approved for Zepbound is 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label), so microdosing would mean injecting any amount below that, as Dr. Anand explains. To illustrate this community practice, Dr. Anand gives hypothetical amounts, not observed use: 1 mg (community practice, no trial), 1.5 mg (community practice, no trial), or 2.3 mg (community practice, no trial). Each community-practice tag here refers to the practice being illustrated, not evidence that people used that particular amount.¹⁴ The second form keeps a labelled amount but stretches the time between weekly shots, or skips a week.¹⁴ Both are described as things people do, not as advice, and UCLA Health is blunt that this is an experimental and unauthorized approach with no microdosing guidelines and no reliable information on its safety.¹⁵

It is, in regulatory terms, off-label use, an approved drug used in an unapproved way, which the reporting notes a clinician may do if they judge it appropriate.¹⁸ The practice is tied to social media and celebrity trends, cost, and gastrointestinal tolerability,¹⁶²⁰²⁴ and because brand-name tirzepatide is sold only in the fixed labelled strengths, community microdosing usually relies on compounded product.¹⁶ The University of Missouri Health Care makes the core catch explicit: only the FDA-approved drugs and doses have been studied, so anything below the lowest approved dosage sits outside the evidence.¹⁷

Commercial programmes have leaned into the trend, which is worth naming so a marketing line is not mistaken for evidence. A telehealth seller of tirzepatide, Alloy, uses the same definition in its marketing, smaller than the recommended starting dose or not escalating, while conceding it is not FDA approved and has not been studied in major clinical trials.²⁷ The much-discussed Noom programme is a separate case: it advertises GLP-1 doses at a fraction of a typical Wegovy starter dose, but Wegovy is semaglutide, and Noom does not offer tirzepatide in its microdosing programme at all.²⁰¹⁸ The parallel questions for semaglutide are handled in our microdosing semaglutide guide.

One recent report gets cited as if it settles the question, so here it is with its own caveats. Healthline reported a records-based analysis, whose primary study could not be verified for this page, in which people on sustained low-dose tirzepatide lost about 5.5 percent of their body weight after one year, against about 2.2 percent for sustained low-dose semaglutide. Healthline defined the tirzepatide group as people with doses spanning at least six months at the labelled starting amount, rather than below it: 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label).¹⁹ The report itself says it did not establish that anyone was intentionally microdosing, so it is not evidence that a chosen microdose works. Medical News Today is direct that there are currently no published studies on the process and no guidelines on how it should occur.²¹

Has Any Trial Tested It

The honest answer is the most important thing on this page: no. No clinical trial or case series located for this page evaluated a deliberate therapeutic tirzepatide regimen below the labelled 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) starting dose.²⁶¹ The lowest amount ever placed in a randomized tirzepatide efficacy trial was a 1 mg (trial dose, not a recommendation, PMID 30293770) arm in the phase 2 dose-finding study,⁶ and the lowest arms in the pivotal phase 3 trials were: SURMOUNT-1, 5 mg (trial dose, not a recommendation, PMID 35658024); SURPASS-1, 5 mg (trial dose, not a recommendation, PMID 34186022); and SURPASS-2, 5 mg (trial dose, not a recommendation, PMID 34170647), each once weekly.³⁴ Below the phase 2 floor of 1 mg (trial dose, not a recommendation, PMID 30293770), amounts appear only in the phase 1 first-in-human programme. It gave healthy volunteers single doses as low as 0.25 mg (trial dose, not a recommendation, PMID 30473097) and four-week weekly doses as low as 0.5 mg (trial dose, not a recommendation, PMID 30473097), followed by a four-week proof-of-concept of 0.5 to 15 mg (trial dose, not a recommendation, PMID 30473097) in people with type 2 diabetes. These were pharmacokinetic and safety doses, not a therapeutic regimen.⁷

SURPASS-1 in type 2 diabetes used arms of 5 mg (trial dose, not a recommendation, PMID 34186022), 10 mg (trial dose, not a recommendation, PMID 34186022), and 15 mg (trial dose, not a recommendation, PMID 34186022). SURPASS-2 against semaglutide used tirzepatide arms of 5 mg (trial dose, not a recommendation, PMID 34170647), 10 mg (trial dose, not a recommendation, PMID 34170647), and 15 mg (trial dose, not a recommendation, PMID 34170647). The first arm listed for each trial was its lowest.⁴⁵ The closest recent study to the microdosing boundary is Amioka's non-randomised cohort in non-diabetic Japanese adults (PMID 42521631). In that non-randomised cohort, the amounts compared were 2.5 mg (trial dose, not a recommendation, PMID 42521631) and 5 mg (trial dose, not a recommendation, PMID 42521631). Both groups initiated at 2.5 mg (trial dose, not a recommendation, PMID 42521631), which is also the Zepbound label starting amount, 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label).²⁵ Patients were not randomised: after four weeks each stayed at the starting dose or moved up to the higher dose by shared decision-making, and in that cohort mean weight loss at six months was 15.3 percent in the lower-dose group and 16.1 percent in the higher-dose group, a difference that was not statistically significant. Because the groups were chosen rather than randomised, those figures do not isolate the effect of dose.²⁵ Even that study operates at the label floor, not below it.

The published literature that pairs tirzepatide with microdosing is commentary and review, not primary dosing data. A narrative review of GLP-1 microdosing describes how shortages pushed providers toward the practice but summarises the drug class generally rather than reporting a tirzepatide study below the Zepbound label starting dose of 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label).²³ A brief report frames subtherapeutic microdosing as an unsupervised patient strategy, driven by cost and shortages, involving research-grade peptides bought online, pen manipulation, and medication sharing, and treats it as a safety concern rather than an investigated dose.²⁴ The registry picture matches: a ClinicalTrials.gov search for tirzepatide microdose or microdosing returns a single observational cohort that is not yet recruiting, and no interventional study below the Zepbound label starting dose of 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label).²⁶

The Labelled Schedule

What is defined, by contrast, is the labelled schedule, and it is the reference point microdosing is measured against. The Zepbound label gives a recommended starting dose of 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) injected subcutaneously once weekly, and the Mounjaro label gives the same 2.5 mg (labelled dose, not a recommendation, Mounjaro FDA label) once-weekly start.¹² The Zepbound label states plainly that the 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) dose is for treatment initiation and is not approved as a maintenance dose.¹ The Zepbound label specifies increases after at least four weeks in 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) increments, so the Zepbound ladder runs 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label), 5 mg (labelled dose, not a recommendation, Zepbound FDA label), 7.5 mg (labelled dose, not a recommendation, Zepbound FDA label), 10 mg (labelled dose, not a recommendation, Zepbound FDA label), 12.5 mg (labelled dose, not a recommendation, Zepbound FDA label), and 15 mg (labelled dose, not a recommendation, Zepbound FDA label) once weekly, and the Mounjaro label uses the same 2.5 mg (labelled dose, not a recommendation, Mounjaro FDA label) increments up to the same 15 mg (labelled dose, not a recommendation, Mounjaro FDA label) ceiling.¹²

For maintenance, the Zepbound label lists 5 mg (labelled dose, not a recommendation, Zepbound FDA label), 10 mg (labelled dose, not a recommendation, Zepbound FDA label), or 15 mg (labelled dose, not a recommendation, Zepbound FDA label) once weekly for weight reduction, and 10 mg (labelled dose, not a recommendation, Zepbound FDA label) or 15 mg (labelled dose, not a recommendation, Zepbound FDA label) once weekly for obstructive sleep apnea, with a maximum of 15 mg (labelled dose, not a recommendation, Zepbound FDA label) once weekly.¹ The Mounjaro maximum is likewise 15 mg (labelled dose, not a recommendation, Mounjaro FDA label) once weekly in adults, and 10 mg (labelled dose, not a recommendation, Mounjaro FDA label) once weekly in pediatric patients aged 10 years and older.² The point for a microdosing reader is simple: 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) is the lowest rung the label defines, and there is no labelled step beneath it.

The products come in fixed presentations. The Zepbound label lists single-dose pens and vials at 2.5 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), 5 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), 7.5 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), 10 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), 12.5 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), and 15 mg/0.5 mL (labelled dose, not a recommendation, Zepbound FDA label), and the Mounjaro label lists the identical strengths (labelled dose, not a recommendation, Mounjaro FDA label).¹² Both 2026 labels also list multi-dose vials and single-patient-use KwikPens that hold four weekly doses.¹² The Mounjaro label specifies a labelled dose volume of 0.6 mL (labelled dose, not a recommendation, Mounjaro FDA label) in a total labelled presentation volume of 2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), at 10 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), 20 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), 30 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), 40 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), 50 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label), and 60 mg/2.4 mL (labelled dose, not a recommendation, Mounjaro FDA label).² The Zepbound label tells vial users to use a syringe capable of measuring 0.5 mL (labelled dose, not a recommendation, Zepbound FDA label) or 0.6 mL (labelled dose, not a recommendation, Zepbound FDA label) and a new syringe and needle each time.¹ The Mounjaro label gives the same instructions for measuring 0.5 mL (labelled dose, not a recommendation, Mounjaro FDA label) or 0.6 mL (labelled dose, not a recommendation, Mounjaro FDA label), including a new syringe and needle each time.² Those fixed strengths are exactly why community microdosing usually turns to compounded product, and why the concentration matters.

What the Lowest Trial Arms Showed

Since 5 mg (trial dose, not a recommendation, PMID 35658024) is the lowest arm SURMOUNT-1 assigned, it is the closest that obesity trial comes to a low dose, and it is still twice the 2.5 mg (labelled dose, not a recommendation, Zepbound FDA label) labelled starting dose. In SURMOUNT-1, the 72-week obesity trial, the 5 mg (trial dose, not a recommendation, PMID 35658024) arm was the lowest of three. That arm lost a mean of 15.0 percent of body weight at week 72, against 3.1 percent on placebo, with the higher arms reaching 19.5 percent at 10 mg (trial dose, not a recommendation, PMID 35658024) and 20.9 percent at 15 mg (trial dose, not a recommendation, PMID 35658024).³ In the same arm, 85 percent of participants reached at least 5 percent weight reduction, versus 35 percent on placebo, and adverse events led 4.3 percent of the 5 mg (trial dose, not a recommendation, PMID 35658024) group to discontinue, against 2.6 percent on placebo.³ For context on what the standard trial doses produced, see the full-dose before and after results from SURMOUNT-1, which sets the baseline that any lower off-label dose is measured against.

In SURPASS-1, the 40-week type 2 diabetes trial, the 5 mg (trial dose, not a recommendation, PMID 34186022) arm reduced HbA1c by 1.87 percent from baseline, an estimated treatment difference versus placebo of -1.91 percent.⁴ The weight result for the SURPASS-1 arm at 5 mg (trial dose, not a recommendation, PMID 34186022) depends on which analysis is used. For that arm, the ClinicalTrials.gov results record NCT03954834 reports a 7.0 kg reduction at week 40 under the efficacy estimand,⁸ while the Mounjaro label reports the trial arm at 5 mg (trial dose, not a recommendation, PMID 34186022) at a 6.3 kg reduction, 5.3 kg more than placebo, under the treatment-regimen estimand that imputes missing data.² They differ only by estimand and analysis population.

One caveat is worth stating rather than papering over: a clean per-arm figure for how many people in the SURPASS-1 arm at 5 mg (trial dose, not a recommendation, PMID 34186022) stopped the drug for adverse events is not available in the open sources. The abstract gives only pooled all-cause discontinuation (66 participants, 14 percent, stopped the study drug), not a per-arm adverse-event number (PMID 34186022).⁴ The nearest labelled figure is discontinuation for gastrointestinal adverse reactions pooled across SURPASS-1 and SURPASS-5, which was 3.0 percent at 5 mg (labelled dose, not a recommendation, Mounjaro FDA label), rising to 6.6 percent at 15 mg (labelled dose, not a recommendation, Mounjaro FDA label), versus 0.4 percent on placebo.² For a sense of what the lowest arms feel like symptomatically, our GLP-1 side effects guide covers the common gastrointestinal pattern.

Converting milligrams to syringe units

To turn a dose into syringe units for your own vial strength, use our tirzepatide reconstitution calculator, which works out the concentration from the amount in the vial and the diluent volume, then converts a milligram amount to syringe units.

Many sub-label amounts do not land on a whole unit. The phase 2 trial included an arm of 1 mg (trial dose, not a recommendation, PMID 30293770), and the phase 1 trial included a weekly dose of 0.5 mg (trial dose, not a recommendation, PMID 30473097).⁶⁷ A U-100 syringe is marked only in whole 1-unit notches,¹² so amounts that fall between notches cannot be measured exactly and get rounded, which is one path to the kind of measuring error the FDA describes.⁹

For a compounded or reconstituted vial the concentration is not set by the label, it depends on how much diluent was added. For the syringe hardware itself, the insulin syringe units chart and the insulin syringe sizes guide show how the notches map to millilitres.

The Risks

The clearest risk sits at the intersection of two facts: microdosing usually uses compounded product, and dosing errors have been reported with compounded injectable semaglutide. The FDA says it has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide products, from patients measuring and self-administering incorrect doses and, in some cases, health care professionals miscalculating them.⁹ It has also received adverse-event reports, some serious, tied to patients using compounded semaglutide or tirzepatide in doses beyond the approved label, whether more product per dose, more frequent dosing, or faster titration.⁹

The scale is on the record. As of May 31, 2026, the FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, according to the FDA page fetched on September 29, 2026.⁹ These are all-cause totals for compounded products, not a dosing-error-specific count, and the FDA notes they are likely underreported because state-licensed pharmacies that are not outsourcing facilities are not required to report.⁹ A separate 2024 FDA alert, specific to compounded semaglutide and not naming tirzepatide, described cases in which patients administered five to 20 times more than the intended dose, with effects including severe nausea, severe vomiting, and severe hypoglycemia (FDA safety alert figure, not a recommendation).¹⁰

Even a low dose is not automatically gentle. A case report describes a serious gastrointestinal event, symptoms resembling acute functional gastric outlet obstruction, in a 57-year-old man with type 2 diabetes on an unspecified low dose of tirzepatide, which resolved after the drug was stopped; the report does not state the dose in milligrams, and it is a single adverse-event report, not evidence about microdosing efficacy (case report, PMID 40026949).²² Cleveland Clinic reports that microdosing has no standard guidelines or American Diabetes Association endorsement, and that compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality.¹³ UCLA Health, Novant Health and Medical News Today describe microdosing as experimental, without clinical-trial evidence of benefit or standard guidelines, and often reliant on compounded product.¹⁵¹⁶²¹

A note on why compounded product is so common here. Tirzepatide was on the FDA drug shortage list from December 15, 2022, and the current order, dated December 19, 2024, determines that the shortage is resolved and replaces an earlier October 2, 2024 decision.¹¹ That order set transition dates for compounding to wind down, until February 18, 2025 for state-licensed 503A pharmacies and until March 19, 2025 for 503B outsourcing facilities, and it confirms that Mounjaro and Zepbound are the only FDA-approved tirzepatide products (these are regulatory transition dates, not guidance on compounding or dosing).¹¹ A brief report notes that ongoing cost and access pressure has kept driving some patients toward unsupervised microdosing and research-grade peptides regardless.²⁴ How tirzepatide is bought and accessed in Vietnam specifically is covered in our tirzepatide in Vietnam guide.

The Short Version

Sources and references

1. 1.ZEPBOUND (tirzepatide) injection prescribing information. Eli Lilly and Company, via DailyMed Structured Product Label, setId 487cd7e7-434c-4925-99fa-aa80b1cc776b. Fetched 2026-09-29. dailymed.nlm.nih.gov / Zepbound label
2. 2.MOUNJARO (tirzepatide) injection prescribing information. Eli Lilly and Company, via DailyMed Structured Product Label, setId d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 2026-08-27. Fetched 2026-09-29. dailymed.nlm.nih.gov / Mounjaro label
3. 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. NCT04184622. PMID 35658024. PubMed PMID 35658024
4. 4.Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 2021. NCT03954834. PMID 34186022. PubMed PMID 34186022
5. 5.Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. NCT03987919. PMID 34170647. PubMed PMID 34170647
6. 6.Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet, 2018. NCT03131687. PMID 30293770. PubMed PMID 30293770
7. 7.Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 2018. NCT02759107. PMID 30473097. PubMed PMID 30473097
8. 8.ClinicalTrials.gov results record, SURPASS-1 (NCT03954834). Change from baseline in body weight and adverse-event modules, public API v2. Fetched 2026-09-29. clinicaltrials.gov / NCT03954834
9. 9.US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 09/01/2026. Fetched 2026-09-29. fda.gov / unapproved GLP-1 drugs
10. 10.US Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. MedWatch bulletin, 07/29/2024. fda.gov / MedWatch semaglutide dosing errors
11. 11.US Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound). Dated December 19, 2024. Fetched 2026-09-29. fda.gov / tirzepatide shortage order
12. 12.University of Florida Health. Giving an Insulin Injection (care sheet). Fetched 2026-09-29. ufhealth.org / insulin injection
13. 13.Cleveland Clinic, Health Essentials. Should You Microdose GLP-1 Medications? July 31, 2026. health.clevelandclinic.org / microdosing GLP-1
14. 14.Hackensack Meridian Health. Is Microdosing GLP-1s Safe? What to Know Before You Try It. May 12, 2026. hackensackmeridianhealth.org / microdosing GLP-1s
15. 15.UCLA Health, Ask the Doctors. GLP-1 microdosing is experimental and unauthorized. Fetched 2026-09-29. uclahealth.org / GLP-1 microdosing
16. 16.Novant Health, Healthy Headlines. Micro-dosing GLP-1 drugs is a bad idea. Here's why. Fetched 2026-09-29. novanthealth.org / micro-dosing GLP-1
17. 17.University of Missouri Health Care, Live Healthy. Thinking About Microdosing GLP-1? 5 Myths Debunked. Katy Williams, MD. Fetched 2026-09-29. livehealthy.muhealth.org / microdosing GLP-1
18. 18.TODAY.com. What Is GLP-1 Microdosing and Does It Lead to Weight Loss? Doctors Explain. Updated Nov. 21, 2025. Carries the Eli Lilly statement on microdosing tirzepatide. today.com / GLP-1 microdosing
19. 19.Healthline. Microdosing GLP-1s Like Wegovy, Zepbound May Still Lead to Weight Loss. September 18, 2026. Secondary reporting of a records-based analysis. healthline.com / microdosing GLP-1 weight loss
20. 20.Healthline. GLP-1 Microdoses Go Mainstream As Noom Introduces Mini Weight Loss Shots. Updated August 11, 2025. healthline.com / Noom mini shots
21. 21.Medical News Today. GLP-1 microdosing for weight loss: Experts weigh the pros and cons. August 12, 2025. medicalnewstoday.com / GLP-1 microdosing
22. 22.Iskander M, Wadhwa M, Kim Y, Singh N, Pathak P. Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide. Cureus, 2025. PMID 40026949. PubMed PMID 40026949
23. 23.Panlilio MA, et al. Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Cureus, 2026. PMID 42668762. PubMed PMID 42668762
24. 24.Trainer N. The 'microdosing' dilemma: balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners, 2026. PMID 42201545. PubMed PMID 42201545
25. 25.Amioka M, et al. Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. Diabetes, Obesity and Metabolism, 2026. PMID 42521631. PubMed PMID 42521631
26. 26.ClinicalTrials.gov registry search for tirzepatide microdose, tirzepatide microdosing, and tirzepatide low dose obesity. Public API v2. Fetched 2026-09-29. clinicaltrials.gov / tirzepatide microdose search
27. 27.Alloy (myalloy.com). Microdosing Tirzepatide for Menopause Weight Loss: What to Know. Last updated August 27, 2026. Commercial telehealth source, treated as marketing. myalloy.com / microdosing tirzepatide